Icon Plc (ICLR)
NASDAQ:ICLR
Want to see ICLR full AI Analyst Report?
ICLR Stock Chart & Stats
$119.68
-$3.85(-1.73%)
At close: 4:00 PM EST
$119.68
-$3.85(-1.73%)
Day’s Range― - ―
52-Week Range$66.57 - $211.00
Previous CloseN/A
Volume330.38K
Average Volume (3M)1.06M
Market Cap
$10.92B
Enterprise Value$13.88B
Total Cash (Recent Filing)$647.29M
Total Debt (Recent Filing)$3.56B
Price to Earnings (P/E)27.9
Beta1.11
Next Earnings
Jul 29, 2026EPS Estimate
2.54Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)6.20
Shares Outstanding76,567,320
10 Day Avg. Volume923,357
30 Day Avg. Volume1,055,577
Financial Highlights & Ratios
PEG Ratio-0.90
Price to Book (P/B)1.55
Price to Sales (P/S)1.73
P/FCF Ratio16.58
Enterprise Value/Market Cap1.27
Enterprise Value/Revenue1.70
Enterprise Value/Gross Profit6.75
Enterprise Value/Ebitda10.67
Forecast
1Y Price Target
$174.25Price Target Upside45.60% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
EPS Forecast (FY)10.55
Revenue Forecast (FY)$8.05B
Bulls Say, Bears Say
Bulls Say
Commercial Momentum / BookingsA sustained book-to-bill >1 and large quarterly net bookings provide durable revenue visibility and backlog conversion over multiple quarters. This pipeline strength supports steadier top-line realization, cushions near-term cancellations, and underpins medium-term capacity planning and resource allocation.
Strong Cash Generation & Manageable LeverageConsistent operating and free cash flow with modest net leverage gives the company durable financial flexibility. It supports reinvestment in labs/clinics, funds share buybacks or debt reduction, and cushions the business through R&D spending cycles and booking variability over the next 2–6 months.
Expanded Service Capabilities & Tech InvestmentGrowth in lab assays, a new Phase I clinic and AI/partner investments deepen differentiated service offerings. These capability expansions raise barriers to entry, enable higher-value end-to-end trials, and should sustainably improve mix, pricing power, and operational efficiency over several quarters.
Bears Say
Accounting Restatements & Control WeaknessesRestatements and disclosed material weaknesses materially weaken financial reporting credibility, increasing audit, remediation and compliance costs. This impairs investor and client confidence, can delay filings, and may constrain strategic actions (M&A, large contracts) until controls are fully remediated.
Margin Compression And Profit DeclineSubstantial margin deterioration signals weaker pricing, mix shifts or higher costs that erode operating leverage. Persistently lower margins reduce free cash flow generation and limit reinvestment or shareholder returns, making recovery dependent on sustained pricing, mix improvement, or structural cost reductions.
Regulatory/reporting Compliance RiskA Nasdaq notice from delayed annual filings highlights governance and reporting risk. Prolonged noncompliance could threaten listing status, distract management, and impede capital market access — a structural risk until filings and remediation restore consistent, timely reporting practices.
Icon News
ICLR FAQ
What was Icon Plc’s price range in the past 12 months?
Icon Plc lowest stock price was $66.57 and its highest was $211.00 in the past 12 months.
What is Icon Plc’s market cap?
Icon Plc’s market cap is $10.92B.
When is Icon Plc’s upcoming earnings report date?
Icon Plc’s upcoming earnings report date is Jul 29, 2026 which is in 34 days.
How were Icon Plc’s earnings last quarter?
Icon Plc released its earnings results on Jun 23, 2026. The company reported $2.5 earnings per share for the quarter, beating the consensus estimate of $2.432 by $0.068.
Is Icon Plc overvalued?
According to Wall Street analysts Icon Plc’s price is currently Undervalued.
Does Icon Plc pay dividends?
Icon Plc does not currently pay dividends.
What is Icon Plc’s EPS estimate?
Icon Plc’s EPS estimate is 2.54.
How many shares outstanding does Icon Plc have?
Icon Plc has 76,567,320 shares outstanding.
What happened to Icon Plc’s price movement after its last earnings report?
Icon Plc reported an EPS of $2.5 in its last earnings report, beating expectations of $2.432. Following the earnings report the stock price went up 10.864%.
Which hedge fund is a major shareholder of Icon Plc?
Currently, no hedge funds are holding shares in ICLR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Icon Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$174.25 (45.60% Upside)
$174.25 (45.60% Upside)
Blogger Sentiment
Bullish
ICLR Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 8.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.6%
Last 30 Days ▲ 7.9%
Last 30 Days ▲ 7.9%
News Sentiment
Very Bullish
Bullish news 96%
Bearish news 4%
Bearish news 4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
6.48%
12-Months-Change
Fundamentals
Return on Equity
5.20%
Trailing 12-Months
Asset Growth
-1.94%
Trailing 12-Months
Company Description
Icon Plc
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company has a strategic alliance with Advarra, Inc. for the development of a connected, research-ready clinical trial site network model. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.
ICLR Company Deck
ICLR Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
Mixed: the call highlighted clear commercial momentum (bookings up 19%, improved win rates and book‑to‑bill of 1.36x), strong cash generation and strategic investments, and management provided conservative yet constructive 2026 guidance with expected margin progression. However, the independent investigation, identified material weaknesses in controls, restatements, significant cost‑to‑complete adjustments (> $50M) and notable margin and earnings deterioration (adjusted EBITDA and EPS declines; GAAP EPS down sharply) are material negatives that temper the outlook.View all ICLR earnings summariesICLR Stock 12 Month Forecast
Average Price Target
$174.25
▲(45.60% Upside)
Technical Analysis
Ownership Overview
― Insiders
34.73% Mutual Funds
57.26% Other Institutional Investors
5.41% Public Companies and
Individual Investors